Meeting
2019 Genitourinary Cancers Symposium
Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
Authors
Anita Gul
Cleveland Clinic, Cleveland, OH
Anita Gul , Neil J. Shah , Charlene Mantia , Hans J. Hammers , Moshe Chaim Ornstein , David F. McDermott , Michael B. Atkins , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 669)
DOI
10.1200/JCO.2019.37.7_suppl.669
Abstract #
669
Poster Bd #
J22
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento
Poster
2017 Genitourinary Cancers Symposium
Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.
First Author: Steven Yip
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah